Autoinflammatory & rare systemic diseases
Beyond diagnosis: exploring the significance of IgG4+ plasma cell count through immunostaining in IgG4-related disease
Main finding · Remission at last follow-upResult — go to the resultOR for remission 6.7 95% CI 1.1–4.42Authors' conclusion
A count of ≥100 IgG4+ plasma cells/HPF may identify patients with a proliferative phenotype, fewer relapses and a higher remission rate.
Study context
- Population
- Patients with biopsy-proven IgG4-RD (Comprehensive Diagnostic Criteria and/or 2019 ACR/EULAR Classification Criteria)
- Participants
- 57 patients
- Exposure
- ≥100 vs <100 IgG4+ plasma cells/HPF in biopsies
- ≥100 IgG4+ plasma cells/HPFn = 18
- <100 IgG4+ plasma cells/HPFn = 39reference
- Outcome
- Association of grade of IgG4+ plasma cell infiltration with clinical or serologic outcomes (remission, relapses)
Methodological detailsmultivariate analysis, log-rank test, ROC analysis
- Multivariate analysis
- Log-rank test
- ROC analysis
Main finding
Remission at last follow-up
OR for remission
6.7
95% CI 1.1–4.42
P = 0.03
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Relapse-free survivalLog-rank test; direction of the ratio not stated | 2.6 (1.2–5.6) | P = 0.01 | |
| 0.20.5125Hazard ratio (log scale) |
Relapse-free survival
- ≥100 IgG4+ plasma cells/HPF had fewer relapses
Relapse by IgG4+ plasma cell count (ROC analysis)
- More than 61 IgG4+ plasma cells: less likely to relapse
Original publication
Beyond diagnosis: exploring the significance of IgG4+ plasma cell count through immunostaining in IgG4-related disease. Clin Exp Rheumatol. Published 20 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →